In an experimental model, diabetes drug shows promise in reducing Alzheimer's disease

Researchers from Boston University School of Medicine (BUSM) have found that the diabetic drug, pramlintide, reduces amyloid-beta peptides, a major component of Alzheimer’s disease (AD) in the brain and improves learning and memory in two experimental AD models. Read & Research Alzheimer’s More

Leave a Reply